Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.

Pruning of ornamental trees by scissors
Lilly said it has no plans for further trials of pegilodecakin and terminated three earlier-stage cancer candidates

Eli Lilly & Co. is going through a reorganization of its cancer research and development operations, and early changes since the pharma turned this responsibility over to the executive team from Loxo Oncology Inc. in December have begun, notably including a decision to pull the plug on further development of pegilodecakin after trial failures in pancreatic and lung cancer.

Lilly reported during its fourth quarter and full-year 2019 sales and earnings call on 30 January that pegilodecakin, a pegylated,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.